Arm A: Atezolizumab and Radiotherapy + Arm B: Atezolizumab
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Penile Cancer
Conditions
Penile Cancer
Trial Timeline
Sep 25, 2018 → Sep 15, 2023
NCT ID
NCT03686332About Arm A: Atezolizumab and Radiotherapy + Arm B: Atezolizumab
Arm A: Atezolizumab and Radiotherapy + Arm B: Atezolizumab is a phase 2 stage product being developed by Roche for Penile Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT03686332. Target conditions include Penile Cancer.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03686332 | Phase 2 | Completed |
Competing Products
8 competing products in Penile Cancer
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Avelumab + enfortumab vedotin | Astellas Pharma | Phase 2 | 52 |
| Pembrolizumab + Standard of care therapy | Merck | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| Placebo QHS and sildenafil and questionnaires + Sildenafil and questionnaire + Trimix combination (Papavarine 30mg/mL Phentholamine 1mg/mL Prostaglandin E1 10 mcg/mmL) and questionnaires | Pfizer | Pre-clinical | 22 |
| Dacomitinib | Pfizer | Phase 2 | 51 |
| Avelumab | Pfizer | Phase 2 | 51 |
| Cabazitaxel | Sanofi | Phase 2 | 51 |
| Retifanlimab | Incyte | Phase 2 | 49 |